The U.S. FDA has announced that use of the popular anti-diabetic drug Actos (pioglitazone HCI) for greater than one year may be associated with an increased risk of bladder cancer. The announcement was based on an investigation of the safety of the drug in a study of more than 190,000 people. A study from France has also indicated the link, causing France and Germany to pull the drug from market. While the U.S. FDA has issued warnings regarding the drugs risks, it remains in use in the United States.
Studies indicate that there is a 40% increased risk of bladder cancer in people who took the drug for more than one year, as compared with those who never took it. Actos, used to manage people with Type 2 diabetes, is made by Takeda Pharmaceuticals North America Inc.
Possible symptoms of bladder cancer can include:
• Abdominal pain
• Blood in the urine
• Painful urination
• Urinary frequency
• Urinary urgency
• Urine leakage (incontinence)
If you have taken Actos and are concerned of the risks, contact your physician for an evaluation of your diabetes and appropriate medical management. If you have developed bladder cancer following the use of Actos, or have questions about the risks of this drug, contact our office for an evaluation of your legal rights.
Our law firm is committed to providing you information regarding defective products, including pharmaceuticals. Our person injury attorneys are available for a free initial consultation to explain your legal rights.